- Hims & Hers has completed the acquisition of Eucalyptus, the parent company of Juniper, expanding its footprint in Canada and strengthening its personalized digital healthcare platform.
- The acquisition follows Hims & Hers becoming the first platform in Canada to offer generic semaglutide to eligible patients, combining Juniper’s weight management expertise with Hims & Hers’ technology, data, and clinical infrastructure.
- The combined platform aims to broaden access to preventive and personalized care across multiple areas, including weight management, sexual health, and hair loss, addressing gaps in prescription affordability and chronic disease management.
- Hims & Hers stated that Canadian patients will continue to receive care from local healthcare providers, while existing Juniper patients will experience uninterrupted treatment as the company scales its healthcare offerings nationwide.
Takeaways:
This acquisition turbocharges Hims & Hers’ Canada growth by giving it a ready-made weight-management business and local provider network, while it becomes the first Canadian platform to offer generic semaglutide alongside its own tech, data, and clinical infrastructure.
Market-wise, the deal should accelerate adoption in high-demand chronic care categories (weight loss, sexual health, hair loss), deepen Hims & Hers’ data moat for personalized care, and create a stronger value proposition around affordability and continuity of care versus stand-alone telehealth players.
Source: Businesswire
